CA-TALKDESK
Talkdesk®, Inc., a global AI-powered contact center leader for enterprises of all sizes, today announced that Simon Horrocks has joined Talkdesk as the Asia-Pacific (APAC) leader to help drive the company’s ongoing growth and expansion as an artificial intelligence (AI) leader in customer experience (CX).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240508118657/en/
Simon Horrocks, Vice President of APAC at Talkdesk (Photo: Business Wire)
Horrocks joins Talkdesk with over 30 years of sales experience managing teams for startups and large organizations in APAC. Based in Sydney, Australia, he is focused on go-to-market acceleration and business expansion for Talkdesk in Australia and New Zealand (ANZ) and Southeast Asia. Horrocks’ appointment further highlights the company’s commitment to being an AI-first CX leader in APAC, as Talkdesk finalizes plans for a regional cloud in Australia and additional regional expansion.
Horrocks joined Talkdesk from Harness.io, where he led the charge in the APAC market as the U.S.-based software delivery platform start-up looked to make its mark in the region. Previously, he worked with several leading and prominent technology companies in APAC, including, AppDynamics, Cisco, IBM, and ScienceLogic.
In addition to Horrocks’ hire, Talkdesk recently promoted Miles Ennis to global sales leader and announced Munil Shah as the company’s chief technology officer (CTO). The appointments follow recent news of Talkdesk launching several groundbreaking and industry-first generative artificial intelligence (GenAI) innovations in CX, including Talkdesk Ascend Connect, Talkdesk Autopilot for Banking, Talkdesk Autopilot for Retail, and Talkdesk Autopilot for Healthcare. Under these new leaders, Talkdesk will capitalize on an extensive global opportunity as companies look to the power of GenAI to help them innovate and expand their businesses, improve customer experiences, and streamline operations.
Talkdesk operates at the forefront of the CX industry, helping companies globally to benefit from a new era of automation and intelligence with contact center solutions powered by Talkdesk AI.
The company was named a Leader in the G2 Spring 2024 Grid® Report for Contact Center category with over 1,800 five-star reviews and ranked #1 in multiple categories, including Enterprise Results and Usability Index for Contact Center Workforce, based on customers’ authentic feedback. Most recently, TrustRadius recognized Talkdesk with 2024 Top Rated Awards for contact center, call center workforce optimization, call recording, and voice over Internet Protocol (VoIP).
Supporting Quotes
William Welch, president and chief operating officer of Talkdesk, said, “APAC is an important market for Talkdesk. With Simon in this critical leadership position in our sales organization, we can drive further growth and success in the region. GenAI offers unparalleled opportunities for companies to elevate customer experience, and Talkdesk will be able to help more organizations globally to reap the benefits.”
Simon Horrocks, vice president of APAC at Talkdesk, commented: “Talkdesk is at the forefront of GenAI innovations in the contact center at a time when businesses need to deliver seamless CX more than ever. Talkdesk is already used by some of the largest banks, e-tailers, and BPOs in APAC, and I’m honored to join the company at such an exciting time, to continue the company’s global expansion momentum.”
About Talkdesk
Talkdesk® is a global cloud contact center leader for enterprises of all sizes. Talkdesk CX Cloud and Industry Experience Clouds help enterprises deliver modern customer service their way. Our trusted, flexible, and innovative contact center platform leverages AI and automation to drive exceptional outcomes for their customers and improve the bottom line. Serving enterprise customers in over 100 countries, we partner with our customers to deliver continuous innovation and breakthrough results. Our unwavering commitment to doing what we say we will do and our investment in the highest levels of security and reliability for our products make us second to none in the industry. Improve customer experiences, increase efficiency, and grow revenue with Talkdesk, a cloud contact center platform built for your industry. Learn more and take a self-guided demo at www.talkdesk.com.
Talkdesk is a registered trademark of Talkdesk, Inc. All product and company names are trademarks™ or registered® trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240508118657/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera1.6.2025 14:00:00 CEST | Press release
Rusfertide plus current standard of care more than doubled clinical response rates across high- and low-risk PV groups, significantly reducing phlebotomy eligibility compared to placebo plus current standard of care, which was the primary endpointAll key secondary endpoints met with statistical significance, including a nearly three-fold reduction in the proportion of patients requiring phlebotomy and a four-fold improvement in hematocrit control in rusfertide arm compared to placebo arm, as well as improvements in patient-reported outcomesNo serious adverse events considered related to rusfertide were reportedRusfertide has received Orphan Drug designation and Fast Track designation from the U.S. FDA Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announced detailed results from the Phase 3, randomized, placebo-controlled VERIFY study evaluating rusfertide in patients with polycythemia vera (PV), which met the primary and all key secondary e
BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA’s Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 202531.5.2025 14:00:00 CEST | Press release
BRUKINSA plus venetoclax demonstrated high response rates and a favorable safety profile across CLL patient types in SEQUOIA Arm D, including those with high-risk del(17p) mutational statusAt 5-year follow-up of SEQUOIA Arm C, BRUKINSA monotherapy showed sustained OS and PFS benefit in hard-to-treat del(17p) CLL patients versus historical data BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today will present new data from the Arm C and D cohorts of the pivotal, global Phase 3 SEQUOIA trial of BRUKINSA® (zanubrutinib). The findings underscore the strong and consistent efficacy of BRUKINSA across CLL patient types, including high-risk mutation status. These data will be presented in two rapid oral presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. Data from the Arm D of SEQUOIA demonstrate that treatment with BRUKINSA plus venetoclax has the potential to drive progression-free survival and overall dee
Andersen Consulting tilføjer Stratence Partners30.5.2025 16:07:00 CEST | Pressemeddelelse
Andersen Consulting udvider sin platform med en samarbejdsaftale med Stratence Partners, der er et konsulentfirma med base i Storbritannien, som hjælper globale virksomheder med at øge markedsandele og forbedre rentabiliteten gennem deres ekspertise inden for prisfastsættelse, strategisk optimering, kommerciel effektivitet og digital transformation. Stratence Partners har en resultatorienteret tilgang og er forpligtet på bæredygtig forandring, hvorved de hjælper deres kunder gennem en unik kombination af konsulentbistand, midlertidige ledelsesindsater og oplæringskurser samt deres egne metoder og løsninger inden for datastyring, datavidenskab (AI), værktøjer og systemer. "Samarbejdet med Andersen Consulting er et spændende skridt for vores firma," sagde Fernando Ventureira, administrerende direktør for Stratence Partners. "I vores arbejde med hos ledere over hele verden har vi erfaret, at deres behov rækker ud over strategisk prisfastsættelse og driftsoptimering. Vores kunder værdsætte
You Up? Grindr’s “Right Now” Goes Global30.5.2025 15:00:00 CEST | Press release
More places, more people – Grindr’s real-time hookup feature makes connecting faster than ever Grindr, the Global Gayborhood in Your Pocket™ with more than 14.6M average monthly active users, today announced the global launch of Right Now, their newest intent-based feature designed to instantly connect people looking for immediate encounters. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250530651954/en/ Grindr's Right Now feature. Right Now is a real-time feed—separate from the app’s main grid that displays profiles—where Grindr users can post text and share photos displayed for one hour, letting other like-minded users know exactly what they’re looking for. “Right Now empowers our users to find exactly what they want, when they want it – without the guesswork,” said AJ Balance, Chief Product Officer at Grindr. “We built this intention-based feature based on feedback from our community so they can connect with like-minded
CAR T Vision Coalition Launches with Ambitious Goal to Double Patients Treated with the Curative Potential of CAR T-cell Therapy by 203030.5.2025 14:00:00 CEST | Press release
Only approximately 2 out of 10 people in the US and 3 out of 10 people in Europe with certain rare, advanced blood cancers receive access to CAR T-cell therapy1,2,3New roadmap report aims to inspire collective action of stakeholder groups and invites additional CAR T-cell therapy leaders to join the coalition Today an international coalition announces the launch of CAR T Vision to unite stakeholders around the shared ambition that every eligible patient should have the opportunity for cure with CAR T-cell therapy. By 2030, the aim is to double the proportion of eligible patients treated with CAR T-cell therapy. As outlined in the new roadmap report, the coalition will work to address access challenges and drive meaningful change in the CAR T-cell therapy healthcare ecosystem with a focus on three critical priorities: increasing awareness and understanding of CAR T-cell therapy; expanding resources and capacity to deliver CAR T-cell therapy; and developing sustainable and innovative fin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom